Features of examination and systemic treatment of malignant neoplasms in gerontological patients


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The world’s population is aging rapidly. Approximately half of all human malignant neoplasms develop in people over 65 years of age. The body of an elderly patient is influenced by three main factors - the actual malignant neoplasm, concomitant diseases and geriatric status. This necessitates the introduction of a systematic and evidence-based integrated approach, including an assessment of the geriatric status of elderly and senile cancer patients into routine clinical practice. Currently, there are many different strategies for choosing the tactics of treating patients in this category, but there are no clinical guidelines approved by Russian oncological organizations. This article presents the most important aspects of the systemic therapy of patients with solid and lymphoproliferative neoplasms in the elderly and senile age, and the main methods of complex geriatric examination.

Толық мәтін

Рұқсат жабық

Авторлар туралы

T. Semiglazova

N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikov

Email: tsemiglazova@mail.ru
St. Petersburg, Russia

Yu. Alekseeva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

E. Tkachenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

S. Sharashenidze

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

I. Baldueva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

S. Volchenkov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. Kovyazin

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

L. Filatova

N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikov

St. Petersburg, Russia

B. Kasparov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

V. Semiglazov

N.N. Petrov National Medical Research Center of Oncology; Pavlov University

St. Petersburg, Russia

S. Protsenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

V. Anisimov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. Belyaev

N.N. Petrov National Medical Research Center of Oncology; Pavlov University

St. Petersburg, Russia

Әдебиет тізімі

  1. Анисимов В.Н., Беляева А.М. (ред.). Онкогеронтология: Руководство для врачей. СПб., 2017. 512 с
  2. Lichtman S.M. Therapy insight: Therapeutic challenges in the treatment of elderly cancer patients. Nat Clin Pract Oncol. 2006;3(2):86-93. doi: 10.1038/ncponc0420.
  3. Wildiers H, Heeren P, Puts M., et al. International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With Cancer. J Clin Oncol. 2014;32:2595-603. Doi: 10.1200/ JCO.2013.54.8347.
  4. Kumar A, Soares H.P, Balducci L., Djulbegovic B. National Cancer Institute. Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol. 2007;25(10):1272-76. doi: 10.1200/JCO.2006.09.2759.
  5. Mohile S.G., Mohamed M.R., Culakova E., et al. A geriatric assessment (GA) intervention to reduce treatment toxicity in older patients with advanced cancer: A University of Rochester Cancer Center NCI community oncology research program cluster randomized clinical trial (CRCT). J Clin Oncol. 2020;38:12009a. Doi: 10.1200/ JCO.2020.38.15_suppl.12009.
  6. Hurria A. Senior adult oncology, version 2.2014. J Natl Compr Cancer Netw. 2014;12:82-126. doi: 10.6004/jnccn.2014.0009.
  7. Yu M, Hazelton W.D., Luebeck G.E., Grady W.M. Epigenetic Aging: More Than Just a Clock When It Comes to Cancer. Cancer Res. 2020;80(3):367-74. doi: 10.1158/0008-5472.CAN-19-0924.
  8. Aapro M.S, Schrijvers D., et al. ESMO handbook of cancer in the senior patient. 2nd edition. 2015.
  9. Balducci L., Corcoran M.B. Antineoplastic chemotherapy of the older cancer patient. Hematol. Oncol Clin North Am. 2000;14(1):193-212, x-xi. doi: 10.1016/s0889-8588(05)70284-7.
  10. Hurria A., Lichtman S.M. Clinical pharmacology of cancer therapies in older adults. Br J Cancer. 2008;98(3):517-22. Doi: 10.1038/ sj.bjc.6604201.
  11. Balducci L., Extermann M. Cancer and aging. An evolving panorama. Hematol Oncol Clin North Am. 2000;14(1):1-16. doi: 10.1016/s0889-8588(05)70274-4. PMID: 10680068.
  12. Переводчикова Н.И., Горбунова В.А. (ред.). Руководство по химиотерапии опухолевых заболеваний. 4-е изд. расширенное и допол. М., 2018. 688 с.
  13. Dombret H., Raffoux E., Gardin C. Acute myeloid leukemia in the elderly. Semin Oncol. 2008;35(4):430-38. Doi: 10.1053/j. seminoncol.2008.04.013.
  14. Repetto L., Fratino L., Audisio R.A., et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002;20(2):494-502. doi: 10.1634/theoncologist.5-3-224.
  15. Balducci L., Repetto L. Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma. Cancer. 2004;100(1):6-11. doi: 10.1002/cncr.11861.
  16. Doorduijn J.K., van der Holt B., van Imhoff G.W., et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2003;21(16):3041-50. Doi: 10.1200/ JCO.2003.01.076.
  17. Gomez H., Mas L., Casanova L., et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol. 1998;16(7):2352-58. doi: 10.1200/JCO.1998.16.7.2352.
  18. Lyman G.H., Kuderer N.M., Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002;112(5):406-11. doi: 10.1016/s0002-9343(02)01036-7.
  19. Patel K.V Epidemiology of anemia in older adults. Semin Hematol. 2008;45(4):210-17. doi: 10.1053/j.seminhematol.2008.06.006.
  20. Procter M., Suter T.M., de Azambuja E., et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 2010;28(21):3422-doi: 10.1200/JCO.2009.26.046.
  21. Chavez-MacGregor M., Zhang N., Buchholz T.A., et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013;31(33):4222-28. Doi: 10.1200/ JCO.2013.48.7884.
  22. Miles D., Baselga J., Amadori D., et al. Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res Treat. 2013;142(1):89-99. doi: 10.1007/s10549-013-2710-z [Epub 2013 Oct 16].
  23. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. Published ahead of print May 21, 2018. doi: 10.1200/JC0.2018.78.8687.
  24. Kanesvaran R, Cordoba R, Maggiore R. Immunotherapy in Older Adults With Advanced Cancers: Implications for Clinical Decision-Making and Future Research. Am Soc Clin Oncol. Educ Book. 2018;38:400-14. doi: 10.1200/EDBK 201435.
  25. Wu Q, Wang Q, Tang X., et al. Correlation between patients' age and cancer immunotherapy efficacy. Oncoimmunol. 2019;8(4):e1568810. doi: 10.1080/2162402X.2019.1568810.
  26. Hong H, Wang Q, Li J, et al. Aging, Cancer and Immunity. J Cancer. 2019;10(13):3021-27. doi: 10.7150/jca.30723.
  27. NCCN Older Adult Oncology Guidelines Version 1.2020. URL: https://www.nccn.org/ professionals/physician_gls/pdf/senior.pdf
  28. Soto-Perez-de-Celis E, Aapro M, Muss H. ASCO 2020: The Geriatric Assessment Comes of Age. Oncol. 2020;25(11):909-12. Doi: 10.1634/ theoncologist.2020-0804.
  29. Hamaker M.E., Schiphorst A.H., ten Bokkel H.D., et al. The effect of a geriatric evaluation on treatment decisions for older cancer patients-a systematic review. Acta Oncol. 2014;53:289-96. doi: 10.3109/0284186X.2013.840741.
  30. Decoster L, Vanacker L, Kenis C, et al. Relevance of Geriatric Assessment in Older Patients With Colorectal Cancer. Clin. Colorectal. Cancer. 2017;16(3):221-29. Doi: 10.1016/j. clcc.2016.07.010.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2021

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>